Top 5 Medical Angel Investors in Belgium (May 2026)

Annie Vereecken

Investment focus

Industry: Biotechnology, Medical, Hospital
Stage:Seed, Series A
Geography: Belgium

Investor stats

Total investments: 6
Lead/follow: no public data

Portfolio highlights

Ziphius — Ziphius Vaccines is a biopharmaceutical company dedicated to developing next-generation vaccines for the prevention of infectious diseases.
Sensolus — Introducing our smart, industrial-grade tracking solution. With battery life of up to ten years, and no additional infrastructure needed.
Allegro Biotech — Allegro has developed the world’s-first custom-tailored, durable, biocompatible, anisotropic, regenerative meniscus cartilage, providing immediate support while also leverage the body’s own healing potential to regenerate human cartilage (proliferation and differentiation of fibrochondrocyte cells).

Show all investments...

Eric Janvier

Investment focus

Industry: Medical, Health Care
Stage:Series A
Geography: Belgium

Investor stats

Total investments: 1
Lead/follow: no public data

Portfolio highlights

Elysia — Elysia developed solution dedicated to quality control laboratories for the production of Radio Pharmaceuticals.

Show all investments...

Herman Verrelst

Investment focus

Industry: Medical, Hospital, Biotechnology
Stage:Series A
Geography: Belgium

Investor stats

Total investments: 1
Lead/follow: no public data

Portfolio highlights

UgenTec — FastFinder is intelligent software that automates sample workflow, ensures your assays are analyzed consistently and cuts data analysis time in half.

Show all investments...

Kenneth A. Buckfire is Co-President and co-founder of Miller Buckfire. Over the course of his career he has advised clients in a broad range of industries (including energy, food products, building products, broadcasting and information services) and has also managed principal investments in distressed companies and in the utility industry. Mr.Buckfire advised Calpine Corporation (named “Most Outstanding Mega Turnaround of 2008″ by the Turnaround Management Association) in its January 2008 reorganization. In 1998, Mr. Buckfire advised 19 independent power producers in the 1998 restructuring of their $11 billion in power contracts with Niagara Mohawk Power Corporation (named “Energy Deal of 1998” by Investment Dealers Digest). Mr. Buckfire has played a leading role in the restructurings of Standard Pacific Corp., Calpine Corporation, Level (3) Communications, Exide Technologies, McLeodUSA, ICG Communications, PSINet Inc., Sirius Satellite Radio, BTI Telecom, CMS Energy, CenterPoint Energy, General Growth Properties, Mirant Corporation (Creditors’ Committee), Horizon Natural Resources (named “Most Outstanding Transaction of 2005” by the Turnaround Management Association), Oakwood Homes, TECO Energy, Centennial Communications, Allegheny International, Foamex, Van Camp Seafood, Walter Industries, Burnham Broadcasting, EUA Power Corporation, Dialog Corporation, Imperial Sugar, CRIIMI MAE and Cajun Electric.Prior to founding Miller Buckfire, Mr. Buckfire was a Managing Director at Dresdner Kleinwort Wasserstein and served as Co-Head of the firm’s financial restructuring group specializing in the restructuring and refinancing of highly leveraged companies. Before joining DrKW, Mr. Buckfire was a Senior Vice President at Lehman Brothers Inc. Mr. Buckfire is on the board of advisors of the Zell-Lurie Institute at The University of Michigan, and on the Board of Directors of the Philharmonic Symphony Society of New York. He is a trustee of Orpheus Orchestra, a member of the Weil Cornell Medical College Dean’s Council, and has been a director and co-founder of several public and private corporations. Mr. Buckfire received his M.B.A. from Columbia University (1987) and his B.A. in Economics and Philosophy from The University of Michigan (1980).

Investment focus

Industry: Medical, Health Care, Life Science
Stage:Series A
Geography: Belgium

Investor stats

Total investments: 1
Lead/follow: 0% lead, 100% follow

Portfolio highlights

Amyl Therapeutics — Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β(Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.

Show all investments...